Gastrectomy is a widely used treatment choice for many diseases, including morbid obesity, peptic ulcer diseases, and gastric neoplasm. Short-term complications of gastrectomy include leakage, intra-abdominal and/or gastrointestinal hemorrhage, and bowel obstruction. In addition, gastrectomy carries the risks of certain long-term complications, such as anastomotic ulcer[@b1], cholelithiasis[@b2][@b3][@b4], and anemia[@b5][@b6]. However, whether patients who have under gone gastrectomy exhibit increased risks of bacterial infection in their digestive system remains unclear.

Gastric acid is a crucial mechanism against digestive system infection[@b7][@b8][@b9][@b10]. Therefore, medical and surgical treatments that decrease gastric acid secretion may increase the risk of digestive tract infection. For example, the use of gastric acid-suppressing agents is associated with an increased risk of *Clostridium difficile* infection[@b11]. Moreover, gastrectomy has been associated with enterocolitis[@b10][@b11][@b12][@b13]. In severe outbreaks of *E. coli*-related colitis, gastrectomy is considered an independent risk factor for infection[@b10].

Without prompt recognition and treatment, pyogenic liver abscess (PLA) can be fatal[@b14]. PLA is commonly associated with an underlying gastrointestinal pathology[@b15]. Hematogenous propagation of pathogens from the digestive tract to the liver was proposed as a pathogenic factor for PLA[@b16]. Theoretically, various conditions causing intestinal infection may increase the PLA risk[@b17][@b18][@b19], and clinically identifying the underlying etiology is an integral part of PLA management.

Based on our research, however, the association between gastrectomy and PLA has not yet been investigated. We hypothesize that patients who have undergone gastrectomy may have a higher risk of PLA than that of patients without a history of gastrectomy. In the present study, we explored the association between gastrectomy and PLA by analyzing data from Taiwan's National Health Insurance Research Database (NHIRD), which contains deidentified medical claims data from 99% of the 23 million residents of Taiwan.

Results
=======

Our study included 33 834 patients with a history of gastrectomy and 135 336 controls. In the gastrectomy cohort, 55.1% of the patients were ≥65 years old, and 67.1% were men ([Table 1](#t1){ref-type="table"}). The mean ages in the gastrectomy and control cohorts were 64.7 (standard deviation \[SD\] = 14.2) and 64.0 (SD = 14.4) years, respectively. Comorbidities were more prevalent in the gastrectomy cohort than in the control cohort (all *P *\< 0.001). The median follow-up duration for the control cohort was 5.30 (range = 0.003--12.0) years, approximately 3 years more than that for the gastrectomy cohort (2.28 years; range = 0.003--12.0).

The overall incidence of PLA was 3.5-fold higher in the gastrectomy cohort than in the control cohort (21.6 vs 5.76 per 10 000 person-y, respectively; [Table 2](#t2){ref-type="table"}). After adjustment for age, sex, and comorbidity, patients with a history of gastrectomy were associated with an increased risk of PLA compared with those without a history of gastrectomy (adjusted HR \[aHR\] = 3.08, 95% CI = 2.60--3.64). The Kaplan--Meier analysis revealed that the cumulative incidence curves of PLA were significantly higher in the gastrectomy cohort than in the control cohort by 0.84% (log-rank test *P *\< 0.001; [Fig. 1](#f1){ref-type="fig"}). Moreover, the two curves of PLA incidence separated gradually during the 12-year follow-up period ([Fig. 1](#f1){ref-type="fig"}), suggesting the association between gastrectomy and PLA was not only related to short-term effects.

We then further analyzed the risk of PLA stratified by sex, age and the presence of comorbidities. The risk of PLA was significantly higher in patients with a history of gastrectomy than in patients without a history of gastrectomy when stratified by sex (aHR = 2.98, 95% CI = 2.18--4.08 for women; aHR = 3.11, 95% CI = 2.55--3.79 for men), age (aHR = 5.16, 95% CI = 2.96--9.01 for patients aged ≤49; aHR = 2.59, 95% CI = 1.89--3.55 for patients aged 50--64; aHR = 3.06, 95% CI = 2.48--3.79 for patients aged ≥65), and comorbidity (aHR = 5.11, 95% CI = 3.94--6.62 for patients without comorbidity; aHR = 2.13, 95% CI = 1.75--2.60 for patients with comorbidities).

[Table 3](#t3){ref-type="table"} illustrates the rates and hazard ratios of PLA associated with different extent of gastrectomy, i.e. partial and total gastrectomy. Patients who had undergone total gastrectomy were 3.67-fold more likely to develop PLA than the controls (95% CI = 2.84--4.74). The aHR was higher for patients with a history of partial gastrectomy (aHR = 2.88; 95% CI = 2.39--3.46) than for the controls.

Finally, we investigated the joint effects of gastrectomy and other PLA risk factors on the risk of PLA ([Table 4](#t4){ref-type="table"}). Compared with the controls without any comorbidity, patients with only cholecystitis had the highest risk of PLA (aHR = 4.26, 95% CI = 1.06--17.2), followed by those with only DM (aHR = 2.94, 95% CI = 2.10--4.12) and those with only cancer (aHR = 2.14, 95% CI = 1.13--4.05; [Table 4](#t4){ref-type="table"}). Moreover, compared with the controls without any comorbidity, patients with a history of gastrectomy and with 3 or more comorbidities were at a significantly increased risk of PLA (aHR = 6.25, 95% CI = 4.42--8.84), followed by those with 2 comorbidities (aHR = 5.54, 95% CI = 4.03--7.62) and those with one comorbidity (aHR = 5.40, 95% CI = 4.17--7.00).

Discussion
==========

This nationwide study is the first to report that patients with a history of gastrectomy are at a 3-fold higher risk of PLA compared with patients without a history of gastrectomy. The PLA risk is significantly increased in patients with previous gastrectomy, with an aHR of 3.08 (95% CI = 2.60--3.64) for PLA, after adjustment for confounding factors. Our results, derived from a large-scale epidemiological database, affirm sporadic observations that gastrectomy is associated with PLA[@b20][@b21]. According to our results, gastrectomy was a risk factor of PLA in patients without other known comorbidities ([Table 4](#t4){ref-type="table"}). Moreover, in [Table 2](#t2){ref-type="table"}, we also showed that gastrectomy was associated with PLA in patients both with and without known comorbidities. In a prospective study investigating infection events after transarterial embolization for hepatocellular carcinoma, liver abscess occurred only in patients who had previously undergone gastrectomy[@b20]. The present study identified that patients with a history of gastrectomy are more vulnerable to PLA.

Because the prognosis of PLA is closely related to prompt diagnosis and management, appropriate screening and management of PLA may be necessary in patients undergoing gastrectomy when there is any clinical suspicion. Moreover, this study raised a potential concern regarding the potential complications of treating morbid obesity through sleeve gastrectomy. More studies are necessary to validate our observations in patients undergoing gastrectomy for different diseases.

Our longitudinal study effectively links gastrectomy and PLA. Unlike cross-sectional and case-control studies, the present study avoids the selection and recall biases and allows to the observation of cumulative incidence of PLA over time ([Fig. 1](#f1){ref-type="fig"}). PLA incidence rises rapidly within the first year after gastrectomy, and the slope of the cumulative incidence curve stabilizes after the first year ([Fig. 1](#f1){ref-type="fig"}), indicating that approximately one-third of the PLAs occurred within the first follow-up year, possibly because several factors affect patient immunity. First, surgery itself alters the immune function[@b22]. Second, patients undergoing gastrectomy may be relatively malnourished for the first few postoperative months. Third, patients undergoing gastrectomy for malignancy might also receive chemotherapy during the perioperative period. Fourth, gastric perforation may be one major indication for gastrectomy. In this case, gastric perforation may be associated with several immunocompromised conditions, such as steroid use, peritonitis and malnutrition. These factors combine to compromise patient immunity temporarily, thus increasing the risk of infection including PLA.

The curves of cumulative PLA incidence in the gastrectomy and control cohorts gradually diverged during the follow-up period ([Fig. 1](#f1){ref-type="fig"}). The aforementioned surgery-related factors that may predispose the patients to PLA do not completely explain why gastrectomy is associated with the PLA risks observed in the present study. A possible factor distorting our observations is the diagnostic bias: The gastrectomy cohort may undergo diagnostic procedures for PLA more frequently than does the control cohort. In the gastrectomy cohort, abdominal imaging was commonly conducted to detect surgery complications and malignancy recurrence or metastasis, which usually occurs during the first few postoperative years. Therefore, the significant difference in the PLA risk exhibited by the 2cohorts cannot be directly attributed to the diagnostic bias.

PLA incidence in Taiwan ranges from 1.12 to 1.86 events per 10 000 person-years[@b23], which is much lower than the incidence reported in our control cohort (5.76 events per 10 000 person-y). As shown in [Table 2](#t2){ref-type="table"}, the incidence of PLA is higher in men than in women and increases with age. In the present study, men accounted for 67.1% of the 2cohorts, and more than half of the participants were older than 65 years. The difference in the incidence rates may be attributable to differences in the age and sex compositions of the control cohort and the general population in Taiwan.

Multiple factors may predispose patients with a history of gastrectomy to PLA. Gastric acid secretion is an important defense mechanism that regulates the number of ingested bacteria and kills many ingested organisms. Gastrectomy affects this mechanism and consequently increases the number of bacterial flora accessing the gastrointestinal mucosa. A microbiological examination of mucosal specimens in patients who have undergone total gastrectomy revealed significant bacterial flora overgrowth, with streptococci being the most abundant species[@b24]. In addition, mucosal ulceration commonly occurs at the gastrectomy site and gastrointestinal anastomosis[@b1], allowing bacterial breakthrough from the digestive tract to the blood stream; both of these factors might contribute to bacterial infection and liver abscess[@b9][@b10][@b20].

Gastrectomy has also been associated with an elevated risk of cholelithiasis[@b25][@b26]; however, the mechanisms underlying this association are not fully understood. Cholelithiasis is a risk factor for PLA[@b27]. As high as 36% of men and 19% of women who have undergone total gastrectomy were reported to develop cholelithiasis[@b26]. Lymph node dissection in the hepatoduodenal ligament, total gastrectomy, and exclusion of the duodenum are risk factors for gallstones after gastrectomy[@b25][@b26]. We also found that patients who had undergone total gastrectomy exhibited a slightly higher PLA risk than that of those undergoing partial gastrectomy ([Table 3](#t3){ref-type="table"}). The proportion of PLA after gastrectomy that is attributable to cholelithiasis is worth investigating.

The compromised post gastrectomy nutritional status[@b28] is another risk factor for PLA[@b29]. Malnutrition may alter the immune system and predispose the patient to infection. A comparison of the nutritional status of patients after different extents of gastrectomy revealed that the quantity of some micronutrients reduced after total gastrectomy. No major differences were found in the nutritional status of the total and partial gastrectomy cohorts.

This study has several limitations. First, the NHIRD provides no detailed information on smoking habits, alcohol consumption, physical activity, economic status, or duration and dosage of steroid use, all of which are potentially confounding factors relevant to this study. In particular, the lack of information regarding DM duration and the status of DM control might bias the results. Second, we were unable to validate the diagnoses of PLA and gastrectomy through a chart review. However, the diagnoses are reliable because we included only hospitalized patients whose diagnoses were strictly audited for reimbursement. Last but not least, the differences in follow-up period may be another bias, considering gastrectomy group had a shorter follow-up period. Theoretically, this bias may potentially underestimate the incidence of PLA in the gastrectomy group, since the individuals of gastrectomy group might die before PLA developed.

Conclusion
==========

In summary, we determined that patients with a history of gastrectomy have an increased risk of PLA. Additional studies on the incidence rates of PLA for patients with gastrectomy history are warranted.

Methods
=======

Data Source
-----------

Taiwan's National Health Insurance (NHI) system is a mandatory universal health insurance program that offers comprehensive medical coverage to all Taiwanese residents[@b20]. The National Health Research Institute (NHRI) of the Ministry of Health and Welfare maintains and releases the NHIRD for use in health service research. To ensure privacy, the NHRI assigns a scrambled, anonymous identification number to the record of each insurant, including sex, birthdate, and registry of medical services; the registry uses the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) diagnostic codes. In this study, we used a subset of the NHIRD containing healthcare data, including inpatient claims and the registry of beneficiaries. All NHI datasets are inter linked with the personal identification number of each insurant. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115). The IRB also specifically waived the consent requirement.

Sampled Participants
--------------------

From inpatient claims data, we identified patients older than 20 years who had undergone partial gastrectomy (ICD-9-OP43.5, 43.6, 43.7, 43.8, 43.81, 43.82, 43.89) or total gastrectomy (ICD-9-OP 43.91 and43.99) from January 1, 2000 to December 31, 2010. Patients whose date of birth and sex were missing in the data and those with preexisting PLA (ICD-9-CM 572.0) were excluded. The index date was defined when the ICD 9 codes of gastrectomy was found within the NHIRD database. Usually, the index date was weeks after the patient was discharged or dead, mainly due to the process time for filing the reimbursement. For each gastrectomy patient, four comparisons were randomly selected from the pool of participants without gastrectomy and PLA at the baseline, frequency matched by the year of index date, age (every 5-year span), sex and comorbidity of diabetes ([Fig. 2](#f2){ref-type="fig"}).

Outcome and Comorbidities
-------------------------

The gastrectomy and control cohorts were followed either until the diagnosis of PLA or until loss to follow-up, death, or December 31, 2011. A diagnosis of one of the following diseases prior to the index date, identified from the hospitalization records, were the considered comorbidities: diabetes mellitus (DM) (ICD-9-CM 250), hypertension (ICD-9-CM 401--405), hyperlipidemia (ICD-9-CM 272), cancer (ICD-9-CM 140--208), chronic obstructive pulmonary disease (COPD) (ICD-9-CM 491, 492, 496), heart failure (ICD-9-CM 428), choledocholithiasis (ICD-9-CM 574), alcoholic liver disease (ICD-9-CM 571.0, 571.1, 571.3), liver cirrhosis (ICD-9-CM 571.2, 571.5, 571.6), cholangitis (ICD-9-CM code 576.1), cholecystitis (ICD-9-CM 575), or pancreatic diseases (ICD-9-CM 577).

Statistical Analyses
--------------------

The distributions of categorical demographic characteristics and comorbidities in the gastrectomy and control cohorts were compared using the Chi-square test. The mean age and mean follow-up duration between both cohorts were examined using the Student's t-test. The cumulative incidence curves of PLA for the 2 cohorts were calculated using the Kaplan--Meier method and compared using the log-rank test. The incidence density rate of PLA in the 2cohorts was calculated for the follow-up period until the end of the study (2011). Univariate and multivariate Cox proportional hazard regressions were used to examine the effect of gastrectomy on the risk of PLA and reported as a hazard ratio (HR) with a 95% confidence interval (CI). The multivariate model was simultaneously adjusted for age, sex, and comorbidities of DM, hypertension, hyperlipidemia, cancer, COPD, heart failure, choledocholithiasis, alcoholic liver disease, liver cirrhosis, cholangitis, cholecystitis, and pancreatic diseases. An additional data analysis was performed to evaluate the combined effects of gastrectomy and PLA-associated risk factors on PLA. All analyses were executed using SAS statistical software (Version 9.4 for Windows; SAS Institute, Inc., Cary, NC, USA); *P* \< 0.05 was considered statistically significant.
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###### Characteristics of patients with and without a history of gastrectomy.

                                              Gastrectomy   *P*-value                 
  ------------------------------------------ ------------- ----------- ------- ------ ---------
  Age, year                                                                             0.99
   ≦49                                           5825         17.2      23300   17.2       
   50--64                                        9364         27.7      37456   27.7       
   ≥65                                           18645        55.1      74580   55.1       
   Mean (SD)^[\#](#t1-fn1){ref-type="fn"}^       64.7         14.2      64.0    14.4    0.001
  Sex                                                                                   0.99
   Female                                        11134        32.9      44536   32.9       
   Male                                          22700        67.1      90800   67.1       
  Comorbidity                                                                              
   Diabetes mellitus                             6138         18.1      24552   18.1    0.99
   Hypertension                                  10589        31.3      27215   20.1   \<0.001
   Hyperlipidemia                                1937         5.73      6753    4.99   \<0.001
   Cancer                                        8467         25.0      5761    4.26   \<0.001
   COPD[a](#t1-fn1){ref-type="fn"}               2747         8.12      7193    5.31   \<0.001
   Heart failure                                 1525         4.51      4318    3.19   \<0.001
   Choledocholithiasis                           3190         9.43      4763    3.52   \<0.001
   Alcoholic liver disease                        564         1.67       702    0.52   \<0.001
   Liver cirrhosis                               1549         4.58      1869    1.38   \<0.001
   Cholangitis                                    404         1.19       850    0.63   \<0.001
   Cholecystitis                                 1470         4.34      1274    0.94   \<0.001
   Pancreatic diseases                            947         2.80      1367    1.01   \<0.001
   Renal disease                                 2753         8.14      5501    4.06   \<0.001
   Diverticulosis                                 397         1.17       681    0.50   \<0.001
   Appendicitis                                   436         1.29      1368    1.01   \<0.001
   IBD[b](#t1-fn1){ref-type="fn"}                 49          0.14       139    0.10    0.04

Chi-square test; ^\#^t-test; SD denotes standard deviation.

^a^COPD = chronic obstructive pulmonary disease; ^b^IBD = Inflammatory Bowel Disease.

###### Incidence rates and hazard ratios of pyogenic liver abscess for patients with and without a history of gastrectomy.

  Outcome                                     Gastrectomy   Crude HR [†](#t2-fn1){ref-type="fn"}(95% CI)   Adjusted HR^[‡](#t2-fn1){ref-type="fn"}^ (95% CI)                                                                           
  ------------------------------------------ ------------- ---------------------------------------------- --------------------------------------------------- ----- -------- ------ -------------------------------------------------- --------------------------------------------------
  All                                             255                          117943                                            21.6                          439   762110   5.76   3.50(3.00, 4.09)[\*\*\*](#t2-fn1){ref-type="fn"}   3.08(2.60, 3.64)[\*\*\*](#t2-fn1){ref-type="fn"}
  Sex                                                                                                                                                                                                                                  
   Female                                         72                           40582                                             17.7                          126   254774   4.95   3.33(2.49, 4.46)[\*\*\*](#t2-fn1){ref-type="fn"}   2.98(2.18, 4.08)[\*\*\*](#t2-fn1){ref-type="fn"}
   Male                                           183                          77360                                             23.7                          313   507335   6.17   3.59(2.99, 4.31)[\*\*\*](#t2-fn1){ref-type="fn"}   3.11(2.55, 3.79)[\*\*\*](#t2-fn1){ref-type="fn"}
  Age, year                                                                                                                                                                                                                            
   ≦49                                            30                           26485                                             11.3                          27    150939   1.79   6.15(3.65, 10.4)[\*\*\*](#t2-fn1){ref-type="fn"}   5.16(2.96, 9.01)[\*\*\*](#t2-fn1){ref-type="fn"}
   50--64                                         72                           35728                                             20.2                          132   223033   5.92   3.17(2.37, 4.22)[\*\*\*](#t2-fn1){ref-type="fn"}   2.59(1.89, 3.55)[\*\*\*](#t2-fn1){ref-type="fn"}
   ≥65                                            153                          55729                                             27.5                          280   388137   7.21   3.54(2.90, 4.31)[\*\*\*](#t2-fn1){ref-type="fn"}   3.06(2.48, 3.79)[\*\*\*](#t2-fn1){ref-type="fn"}
  Comorbidity^[§](#t2-fn1){ref-type="fn"}^                                                                                                                                                                                             
   No                                             82                           47424                                             17.3                          195   541683   3.60   4.69(3.62, 6.07)[\*\*\*](#t2-fn1){ref-type="fn"}   5.11(3.94, 6.62)[\*\*\*](#t2-fn1){ref-type="fn"}
   Yes                                            173                          70519                                             24.5                          244   220527   11.1   2.08(1.71, 2.53)[\*\*\*](#t2-fn1){ref-type="fn"}   2.13(1.75, 2.60)[\*\*\*](#t2-fn1){ref-type="fn"}

PY, person-years; Rate^\#^, incidence rate per 10 000 person-years.

Crude HR^†^, relative hazard ratio.

Adjusted HR^‡^, hazard ratio adjusted for age, sex, and comorbidities of DM, hypertension, hyperlipidemia, cancer, COPD, heart failure, choledocholithiasis, alcoholic liver disease, liver cirrhosis, cholangitis, cholecystitis, pancreatic diseases, renal disease, diverticulosis, appendicitis, and IBD.

Comorbidity^§^: Patients with any one of the comorbidities (DM, hypertension, hyperlipidemia, cancer, COPD, heart failure, choledocholithiasis, alcoholic liver disease, liver cirrhosis, cholangitis, cholecystitis, pancreatic diseases, renal disease, diverticulosis, appendicitis, and IBD) were classified as the comorbidity cohort.

\*\*\**P *\< 0.001.

###### Incidence rates and hazard ratios of pyogenic liver abscess for patients who have undergone partial and total gastrectomy.

  Variable                            Event    PYs     Rate                  Crude HR (95% CI)                                 Adjusted HR (95% CI)
  ---------------------------------- ------- -------- ------ -------------------------------------------------- --------------------------------------------------
  Control (N = 135336)                 439    762110   5.76                         1.00                                               1.00
  Gastrectomy                                                                                                   
   Partial gastrectomy (N = 24541)     180    90124    20.0   3.27(2.75, 3.89)[\*\*\*](#t3-fn1){ref-type="fn"}   2.88(2.39, 3.46)[\*\*\*](#t3-fn1){ref-type="fn"}
   Total gastrectomy (N = 9293)        75     27819    27.0   4.24(3.32,5.42)[\*\*\*](#t3-fn1){ref-type="fn"}    3.67(2.84, 4.74)[\*\*\*](#t3-fn1){ref-type="fn"}

PY, person-years; Rate^\#^, incidence rate per 10 000 person-years.

Crude HR^†^, relative hazard ratio.

Adjusted HR^‡^, hazard ratio adjusted for age, sex, and comorbidities of DM, hypertension, hyperlipidemia, cancer, COPD, heart failure, choledocholithiasis, alcoholic liver disease, liver cirrhosis, cholangitis, cholecystitis, pancreatic diseases, renal disease, diverticulosis, appendicitis, and IBD.

\*\*\**P *\< 0.001.

###### Combined effects of gastrectomy and pyogenic liver abscess-associated risk factors on pyogenic liver abscess.

  Variable                                  N     No. of Events   Rate^[\#](#t4-fn1){ref-type="fn"}^   Adjusted HR^[†](#t4-fn1){ref-type="fn"}^(95% CI)   Adjusted HR^[§](#t4-fn1){ref-type="fn"}^(95% CI)         
  -------------------------------------- ------- --------------- ------------------------------------ -------------------------------------------------- -------------------------------------------------- ------ ----------------------------------------------
  One risk factor                                                                                                                                                                                                  
   Gastrectomy                            11903        87                        17.6                                        5.20                           (4.04, 6.71)[\*\*\*](#t4-fn1){ref-type="fn"}     3.41   (2.90, 4.02)[\*\*\*](#t4-fn1){ref-type="fn"}
   Cholecystitis                           208          2                        17.3                                        4.26                             (1.06, 17.2)[\*](#t4-fn1){ref-type="fn"}       1.59     (1.07, 2.36)[\*](#t4-fn1){ref-type="fn"}
   Diabetes mellitus                      6735         41                        11.4                                        2.94                           (2.10, 4.12)[\*\*\*](#t4-fn1){ref-type="fn"}     2.27   (1.93, 2.68)[\*\*\*](#t4-fn1){ref-type="fn"}
   Cancer                                 2289         10                        9.19                                        2.14                             (1.13, 4.05)[\*](#t4-fn1){ref-type="fn"}       1.13                   (0.89, 1.44)
   Hypertension                           7428         19                        5.10                                        1.05                                           (0.65, 1.69)                                                  
   Hyperlipidemia                          706          4                        10.4                                        2.59                                           (0.96, 6.97)                                                  
   COPD^[a](#t4-fn1){ref-type="fn"}^      1563          4                        5.30                                        0.98                                           (0.36, 2.66)                                                  
   Heart failure                           427          1                        5.31                                        1.03                                           (0.15, 7.39)                                                  
   Choledocholithiasis                     968          3                        5.53                                        1.31                                           (0.42, 4.08)                                                  
   Alcoholic liver disease                 103          1                        17.3                                        5.15                                           (0.72, 36.8)                                                  
   Liver cirrhosis                         233          1                        10.7                                        2.58                                           (0.36, 18.4)                                                  
   Cholangitis                             26           0                        0.00                                        ---                                                ---                                                       
   Pancreatic diseases                     118          0                        0.00                                        ---                                                ---                                                       
   Renal disease                           108          0                        0.00                                        ---                                                ---                                                       
   Diverticulosis                           4           0                        0.00                                        ---                                                ---                                                       
   Appendicitis                             1           0                        0.00                                        ---                                                ---                                                       
  IBD^[b](#t4-fn1){ref-type="fn"}^          4           0                        0.00                                        ---                                                ---                                                       
  Gastrectomy with any one comorbidity    10812        83                        21.9                                        5.40                           (4.17, 7.00)[\*\*\*](#t4-fn1){ref-type="fn"}                                  
  Gastrectomy with any 2 comorbidities    6367         49                        25.2                                        5.54                           (4.03, 7.62)[\*\*\*](#t4-fn1){ref-type="fn"}                                  
  Gastrectomy with \>2 comorbidities      5416         41                        31.0                                        6.25                           (4.42, 8.84)[\*\*\*](#t4-fn1){ref-type="fn"}                                  

Rate^\#^, per 10 000 person-year;

Adjusted HR^†^: multivariate analysis including age and sex.

Adjusted HR^§^: multivariate analysis including age, sex, cholecystitis, diabetes mellitus, and cancer.

\**P *\< 0.05; \*\*\**P *\< 0.001.

^a^CO*P*D = chronic obstructive pulmonary disease; ^b^IBD = Inflammatory Bowel Disease.
